急性心肌梗塞国产重组链激酶静脉溶栓的疗效和安全性

The therapentic effect and safety of intraverous China-made recombinant stveptokinase in patients with acute myocardial infarction

目的观察国产重组链激酶(r-SK)静脉溶栓治疗急性心肌梗塞(AMI)的疗效及安全性。方法选择12例AMI患者应用r-SK静脉溶栓治疗,观察临床症状、心电图、心肌酶谱的变化,判断血管再通率。结果12例AMI患者溶栓再通率85.7%,5例发病6～24h溶栓再通1例,再通率20%,两者相比差异有显著性(P<0.05)。结论AMI患者选用国产r-SK静脉溶栓是安全、有效的治疗方法。

Objective:To observe the therapentic effect and Safety with AMI.Methods:12 Patients with AMI were treated by intravenous r-SK.The reperfusion rate was evaluted of the improvements of clinical symptows and signs、EKG and myocandium enayme.Results:Of the 12 patients,the reperfusiou rate was 58.3%.The reperfusion rate of the patients who received thrombolysis less than 6 hours after the ouset of symptoms was much higher than that of 6～24 hours.Conclusion:Intravenous China-made r-SK in patients with AMI appeareted to be safe and effective.